摘要
目的 探讨安罗替尼联合贝伐珠单抗治疗IDH野生型胶质母细胞瘤(IDH-wildtype glioblastoma)的疗效。方法 回顾性收集2019—2022年山东省肿瘤医院16例经临床影像、组织病理、基因检测诊断确诊的IDH野生型胶质母细胞瘤并给予盐酸安罗替尼联合贝伐珠单抗注射液治疗的患者临床资料,并对患者无进展生存期、总生存时间及不良反应等情况进行分析。结果 患者术后中位无进展生存期(media progression free survival, mPFS)为13.29个月,中位总生存期(media overall survival, mOS)为22.65个月。在不良反应方面,出现骨髓抑制14例(87.5%)、口腔溃疡1例(6.25%)、轻度肝功能异常2例(12.5%)、胆红素升高1例(6.25%)、高脂血症4例(25%)、胃肠道反应2例(12.5%)。各种不良反应事件中,共发生3-4级不良反应5例(31.25%)。结论 盐酸安罗替尼联合贝伐珠单抗注射液治疗IDH野生型胶质母细胞瘤对延长患者的生存期有一定疗效。
Objective To investigate the efficacy and safety of anlotinib hydrochloride combined with bevacizumab in the treatment of IDH wild-type glioblastoma.Methods We retrospectively analyzed the clinical data of 16 patients with IDH wild-type glioblastoma diagnosed by clinical imaging,histopathology,and genetic testing at Shandong Cancer Hospital from 2019 to 2022.These patients were treated with anlotinib hydrochloride combined with bevacizumab injection.The overall survival(OS),progression-free survival(PFS),and adverse reactions of the patients were statistically analyzed.Results The median progression-free survival(mPFS)was 13.29 months,and the median overall survival(mOS)was 22.65 months.The main adverse reactions included bone marrow suppression(14 cases,87.5%),oral ulcer(1 case,6.25%),mild liver dysfunction(2 cases,12.5%),elevated bilirubin(1 case,6.25%),hyperlipidemia(4 cases,25%),and gastrointestinal reactions(2 cases,12.5%).Grade 3-4 adverse reactions occurred in 5 patients(31.25%).Conclusion Anlotinib hydrochloride combined with bevacizumab injection can significantly prolong the survival period in patients with IDH wild-type glioblastoma.
作者
曲冰
张慧
郭洪刚
赵艳芹
司晓男
王体
颜玉
张慧
QU Bing;ZHANG Hui;GUO Honggang;ZHAO Yanqin;SI Xiaonan;WANG Ti;YAN Yu;ZHANG Hui(Neurosurgery Department,Sishui County People′s Hospital,Jining 273299,China;Rare Oncology Department,Shandong Cancer Hospital,Jinan 250117,China)
出处
《济宁医学院学报》
2025年第1期48-51,共4页
Journal of Jining Medical University
